The CUSMA renegotiation and issues related to the pharmaceutical industry in Canada. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, as well as the Intellectual Property performance review, as noted in budget 2026. Free trade agreements as they relate to biomanufacturing industry in Canada. Engage, as a stakeholder, to provide input into the re-negotiation of the Canada USA Mexico trade agreement "CUSMA" Patented Medicines Regulations modernization as outlined in Budget 2026, that will leverage existing technology, enabling faster and more cost effective procedural processes. Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB) Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines. Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.
Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB) Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB) Patent Medicines Pricing Review Board reforms, regarding both the revised regulations and draft guidelines Patented Medicines (Notice of Compliance) Regulations as it relates to regulation of intellectual property for therapeutic products. Novartis is working with our industry associations (Innovative Medicines Canada and BIOTECanada) to provide a written response to Guideline consultation process and will provide our own corporate submission. Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.